Display options
Cite
Cuatrecasas M, Gorostiaga I, Riera C, et al. Complete Loss of EPCAM Immunoexpression Identifies . Cancers (Basel). 2020;12(10)doi: 10.3390/cancers12102803.
Cuatrecasas, M., Gorostiaga, I., Riera, C., Saperas, E., Llort, G., Costa, I., Matias-Guiu, X., Carrato, C., Navarro, M., Pineda, M., Dueñas, N., Brunet, J., Marco, V., Trias, I., Busteros, J. I., Mateu, G., Balaguer, F., Fernández-Figueras, M. T., Esteller, M., & Musulén, E. (2020). Complete Loss of EPCAM Immunoexpression Identifies . Cancers, 12(10), . https://doi.org/10.3390/cancers12102803
Cuatrecasas, Míriam, et al. "Complete Loss of EPCAM Immunoexpression Identifies ." Cancers vol. 12,10 (2020). doi: https://doi.org/10.3390/cancers12102803
Cuatrecasas M, Gorostiaga I, Riera C, Saperas E, Llort G, Costa I, Matias-Guiu X, Carrato C, Navarro M, Pineda M, Dueñas N, Brunet J, Marco V, Trias I, Busteros JI, Mateu G, Balaguer F, Fernández-Figueras MT, Esteller M, Musulén E. Complete Loss of EPCAM Immunoexpression Identifies . Cancers (Basel). 2020 Sep 29;12(10). doi: 10.3390/cancers12102803. PMID: 33003511; PMCID: PMC7599495.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 Sep 29;12(10). doi: 10.3390/cancers12102803.

Complete Loss of EPCAM Immunoexpression Identifies .

Cancers

Míriam Cuatrecasas, Iñigo Gorostiaga, Cristina Riera, Esteban Saperas, Gemma Llort, Irmgard Costa, Xavier Matias-Guiu, Cristina Carrato, Matilde Navarro, Marta Pineda, Núria Dueñas, Joan Brunet, Vicente Marco, Isabel Trias, José Ignacio Busteros, Gemma Mateu, Francesc Balaguer, María-Teresa Fernández-Figueras, Manel Esteller, Eva Musulén

Affiliations

  1. Department of Pathology, Center of Biomedical Diagnosis (CDB), Hospital Clínic, 08036 Barcelona, Spain.
  2. Universitat de Barcelona (UB), 08007 Barcelona, Spain.
  3. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 08036 Barcelona, Spain.
  4. Department of Pathology, Hospital Universitario de Araba, 01009 Vitoria-Gasteiz, Spain.
  5. Gastroenterology Department, Hospital Universitari General de Catalunya-Grupo Quirónsalud, Sant Cugat del Valles, 08195 Barcelona, Spain.
  6. Universitat Internacional de Catalunya (UIC), Sant Cugat del Vallès, 08017 Barcelona, Spain.
  7. Oncology Department, Parc Taulí Hospital Universitari, Sabadell, 08208 Barcelona, Spain.
  8. Oncology Department, Consorci Sanitari de Terrassa, Terrassa, 08208 Barcelona, Spain.
  9. Department of Pathology, Parc Taulí Hospital Universitari, Sabadell, 08208 Barcelona, Spain.
  10. Department of Pathology, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
  11. Department of Pathology, Hospital Universitari Arnau de Vilanova, 25198 Lleida, Spain.
  12. Universitat de Lleida, IRBLLEIDA, 25003 Lleida, Catalonia, Spain.
  13. Centro de Investigación Biomédica en Red Cancer (CIBERONC), 28029 Madrid, Spain.
  14. Department of Pathology, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain.
  15. Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program, Hospitalet de Llobregat, 08908 Barcelona, Spain.
  16. Hereditary Cancer Program, Catalan Institute of Oncology, Institut d'Investigació Biomèdica de Girona (IDIBGI), Universitat de Girona, 17190 Girona, Spain.
  17. Department of Pathology, Hospital Quirónsalud Barcelona, 08023 Barcelona, Spain.
  18. Department of Pathology, Hospital Platón, 08006 Barcelona, Spain.
  19. Department of Pathology, Hospital Universitario Príncipe de Asturias, 28805 Alcalá de Henares, Madrid, Spain.
  20. Department of Pathology, University Hospital Josep Trueta, 17007 Girona, Spain.
  21. Gastroenterology Department, Institut de Malalties Digestives i Metabòliques, Hospital Clínic, 08036 Barcelona, Spain.
  22. Department of Pathology, Hospital Universitari General de Catalunya-Grupo Quirónsalud, Sant Cugat del Vallès, 08190 Barcelona, Spain.
  23. Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Barcelona, Spain.
  24. Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain.

PMID: 33003511 PMCID: PMC7599495 DOI: 10.3390/cancers12102803

Abstract

The use of epithelial cell adhesion molecule (EPCAM) immunohistochemistry (IHC) is not included in the colorectal cancer (CRC) screening algorithm to detect Lynch syndrome (LS) patients. The aim of the present study was to demonstrate that EPCAM IHC is a useful tool to guide the LS germ-line analysis when a loss of MSH2 expression was present. We retrospectively studied MSH2 and EPCAM IHC in a large series of 190 lesions composed of malignant neoplasms (102), precursor lesions of gastrointestinal (71) and extra-gastrointestinal origin (9), and benign neoplasms (8) from different organs of 71 patients suspicious of being LS due to

Keywords: EPCAM; colon polyps; colorectal cancer; immunohistochemistry; lynch syndrome

References

  1. Food Chem Toxicol. 2018 Aug;118:198-203 - PubMed
  2. J Clin Oncol. 2011 Jan 10;29(2):223-7 - PubMed
  3. Hum Pathol. 2014 Jul;45(7):1388-96 - PubMed
  4. J Clin Pathol. 2011 May;64(5):415-20 - PubMed
  5. Cancer Prev Res (Phila). 2011 Oct;4(10):1556-62 - PubMed
  6. Histopathology. 2016 Aug;69(2):322-8 - PubMed
  7. Clin Epigenetics. 2015 Jul 22;7:71 - PubMed
  8. Fam Cancer. 2015 Mar;14(1):61-8 - PubMed
  9. J Mol Diagn. 2009 May;11(3):238-47 - PubMed
  10. Cancer Prev Res (Phila). 2012 Apr;5(4):574-82 - PubMed
  11. Gastroenterol Hepatol. 2016 Oct;39(8):500-7 - PubMed
  12. Genet Med. 2019 Oct;21(10):2167-2180 - PubMed
  13. Clin Genet. 2012 Jul;82(1):97-9 - PubMed
  14. Histopathology. 2017 Mar;70(4):664-669 - PubMed
  15. QJM. 2016 Mar;109(3):151-8 - PubMed
  16. Lancet Oncol. 2011 Jan;12(1):49-55 - PubMed
  17. Nat Rev Cancer. 2015 Mar;15(3):181-94 - PubMed
  18. Hum Pathol. 2013 Mar;44(3):412-6 - PubMed
  19. Hum Mutat. 2009 Feb;30(2):197-203 - PubMed
  20. J Pathol. 2012 Apr;226(5):764-74 - PubMed
  21. Mod Pathol. 2012 May;25(5):722-30 - PubMed
  22. Genet Med. 2016 Aug;18(8):823-32 - PubMed
  23. Gastroenterology. 2008 Aug;135(2):429-37 - PubMed
  24. Oncotarget. 2016 Mar 22;7(12):13372-87 - PubMed
  25. Eur J Hum Genet. 2020 Mar;28(3):277-286 - PubMed
  26. Crit Rev Oncol Hematol. 2017 Aug;116:38-57 - PubMed
  27. Hum Mutat. 2019 Feb;40(2):142-161 - PubMed
  28. Mod Pathol. 2018 Oct;31(10):1608-1618 - PubMed
  29. J Mol Diagn. 2011 Jan;13(1):93-9 - PubMed
  30. Genes Chromosomes Cancer. 2013 Sep;52(9):845-54 - PubMed
  31. Mod Pathol. 2005 Aug;18(8):1095-101 - PubMed
  32. Gastroenterology. 2014 Aug;147(2):502-26 - PubMed
  33. Mod Pathol. 2017 Aug;30(8):1144-1151 - PubMed
  34. J Mol Diagn. 2005 May;7(2):160-70 - PubMed
  35. Eur J Cancer. 2018 Nov;104:91-103 - PubMed
  36. Mod Pathol. 2012 Jun;25(6):911-6 - PubMed
  37. Cancer. 2019 Sep 15;125(18):3172-3183 - PubMed
  38. Nat Genet. 2014 Feb;46(2):107-115 - PubMed
  39. Oncotarget. 2020 Apr 07;11(14):1244-1256 - PubMed
  40. Lancet Oncol. 2011 Jan;12(1):5-6 - PubMed
  41. Histopathology. 2009 Oct;55(4):414-22 - PubMed
  42. Gastroenterology. 2004 Jan;126(1):42-8 - PubMed
  43. Genes Chromosomes Cancer. 2009 Aug;48(8):737-44 - PubMed
  44. Gastroenterology. 2010 Jun;138(6):2044-58 - PubMed
  45. Nat Rev Dis Primers. 2016 Dec 01;2:16086 - PubMed
  46. Gut. 2000 Jul;47(1):37-42 - PubMed
  47. Front Biosci. 2008 Jan 01;13:3096-100 - PubMed
  48. Cancer Res. 2010 Apr 15;70(8):3098-108 - PubMed
  49. Nat Genet. 2009 Jan;41(1):112-7 - PubMed

Publication Types

Grant support